In this study, we investigated the roles of secretory NPC2-mediated free cholesterol levels as biomarkers in patients undergoing sorafenib treatment and evaluated its impacts on acquired sorafenib resistance in HCC. The gene discussed is NPC2; the disease is hepatocellular carcinoma.